AB5636P
Anti-Cannabinoid Receptor 1 Antibody, NT
Chemicon®, from rabbit
Sinonimo/i:
CB1
Autenticatiper visualizzare i prezzi riservati alla tua organizzazione & contrattuali
About This Item
Codice UNSPSC:
12352203
eCl@ss:
32160702
NACRES:
NA.41
Prodotti consigliati
Origine biologica
rabbit
Livello qualitativo
Forma dell’anticorpo
affinity purified immunoglobulin
Tipo di anticorpo
primary antibodies
Clone
polyclonal
Purificato mediante
affinity chromatography
Reattività contro le specie
human, rat, mouse
Produttore/marchio commerciale
Chemicon®
tecniche
ELISA: suitable
western blot: suitable
N° accesso NCBI
N° accesso UniProt
Condizioni di spedizione
dry ice
modifica post-traduzionali bersaglio
unmodified
Informazioni sul gene
human ... CNR1(1268)
mouse ... Cnr1(12801)
Specificità
Recognizes human Cannabinoid Receptor 1 (CB1). The immunogen shows no significant sequence homology with CB2 or other receptors.
Immunogeno
A 14 amino acid N-terminus peptide sequence (aa 1-14) (Gerard et al. 1991; Gerard et al.
1990; Shire et al. 1995; Matsuda et al. 1990; Ho et al. 1996; Chakraborty et al. 1995).
1990; Shire et al. 1995; Matsuda et al. 1990; Ho et al. 1996; Chakraborty et al. 1995).
Epitope: N-terminus
Applicazioni
Research Category
Neuroscience
Neuroscience
Research Sub Category
Neuroinflammation & Pain
Neurotransmitters & Receptors
Neuroinflammation & Pain
Neurotransmitters & Receptors
This Anti-Cannabinoid Receptor 1 Antibody, N-terminus is validated for use in ELISA, WB for the detection of Cannabinoid Receptor 1.
Western blot: 1-10 μg/mL using ECL. Expected sizes are ~60kDa and 80-84kDa under reducing conditions.
ELISA: 1:10,000-1:100,000 using 50-100 ng control peptide (Cat. No. AG357) per well.
Optimal working dilutions must be determined by the end user.
ELISA: 1:10,000-1:100,000 using 50-100 ng control peptide (Cat. No. AG357) per well.
Optimal working dilutions must be determined by the end user.
Descrizione del bersaglio
~60kDa and 80-84kDa
Stato fisico
Affinity Purified immunoglobulin. Liquid in 100mM Tris, pH 7.5, containing 0.2% BSA and 0.05% sodium azide.
ImmunoAffinity Purified
Stoccaggio e stabilità
Maintain for 1 year at -20°C from date of shipment. Aliquot to avoid repeated freezing and thawing. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap.
Risultati analitici
Control
Brain tissue
Brain tissue
Altre note
Concentration: Please refer to the Certificate of Analysis for the lot-specific concentration.
Note legali
CHEMICON is a registered trademark of Merck KGaA, Darmstadt, Germany
Esclusione di responsabilità
Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.
Non trovi il prodotto giusto?
Prova il nostro Motore di ricerca dei prodotti.
Codice della classe di stoccaggio
12 - Non Combustible Liquids
Classe di pericolosità dell'acqua (WGK)
WGK 2
Punto d’infiammabilità (°F)
Not applicable
Punto d’infiammabilità (°C)
Not applicable
Certificati d'analisi (COA)
Cerca il Certificati d'analisi (COA) digitando il numero di lotto/batch corrispondente. I numeri di lotto o di batch sono stampati sull'etichetta dei prodotti dopo la parola ‘Lotto’ o ‘Batch’.
Possiedi già questo prodotto?
I documenti relativi ai prodotti acquistati recentemente sono disponibili nell’Archivio dei documenti.
Cannabinoid control of brain bioenergetics: Exploring the subcellular localization of the CB1 receptor.
Hebert-Chatelain, E; Reguero, L; Puente, N; Lutz, B; Chaouloff, F; Rossignol, R; Piazza et al.
Molecular Metabolism null
C Song et al.
Life sciences, 56(23-24), 1983-1989 (1995-01-01)
To study the N-linked glycosylation properties of the CB1 receptor, rat brain membranes were treated with exo- and endoglycosidases. For visualizing CB1 receptors, an antipeptide antibody was raised against the N-terminal 14 amino acids and used to specifically detect the
Andrew P Ray et al.
Behavioural brain research, 196(1), 30-36 (2008-08-30)
Cisplatin chemotherapy frequently causes severe vomiting in two temporally separated clusters of bouts dubbed the acute and delayed phases. Cannabinoids can inhibit the acute phase, albeit through a poorly understood mechanism. We examined the substrates of cannabinoid-mediated inhibition of both
Il team dei nostri ricercatori vanta grande esperienza in tutte le aree della ricerca quali Life Science, scienza dei materiali, sintesi chimica, cromatografia, discipline analitiche, ecc..
Contatta l'Assistenza Tecnica.